SB273005 is a potent integrin inhibitor with applications in the inhibition of αvβ3 and αvβ5 receptors (Ki = 1.2 nM and 0.3 nM, respectively); it inhibits human osteoclast-mediated bone resorption in vitro (IC50 = 11 nM); in combination with lamifiban, it inhibits tumor cell adhesion to vascular extracellular matrix (ECM) in blood containing MDA-MB-231 cells; in rat models of bone resorption and osteoporosis, it suppresses parathyroid hormone-stimulated calcemic response and prevents bone loss; in rats with adjuvant-induced arthritis, it significantly alleviates arthritis symptoms; it induces acute, transient necrosis of vascular smooth muscle cells (VSMCs) in the aorta and renal arteries of mice at high doses; and in pregnant mice, it reverses the Th1 cell-derived IL-2 reduction and Th2 cell-derived IL-10 elevation.